Cool Mint Hits 30% in JUUL Relaunch Market

---

The FDA Just Authorized Its First Non-Tobacco, Non-Menthol ENDS Products, and JUUL's Cool Mint May Be the Biggest Winner

On May 5, 2026, the FDA authorized the marketing of four Glas electronic nicotine delivery systems, including pods labeled Classic Menthol, Fresh Menthol, Gold, and Sapphire. The agency explicitly called this its "first authorization of non-tobacco and non-menthol ENDS products." That sentence, buried in a press release about a company most consumers have never heard of, rewrites the calculus for every flavored vape product sitting in the FDA's premarket tobacco product application (PMTA) pipeline. JUUL's Cool Mint sits near the top of that queue.

Before this authorization, the FDA had only cleared tobacco-flavored and menthol-flavored ENDS products through the PMTA pathway. The Glas decision broke that barrier. It established that the agency is willing to greenlight flavors outside those two categories, provided the applicant demonstrates sufficient youth-access mitigation. Glas met that standard with a Bluetooth-paired device that requires government ID verification and random biometric check-ins. The technology is restrictive, but the precedent is permissive: flavored ENDS can now reach the legal U.S. market.

For Cool Mint, the implications are direct. JUUL already secured FDA authorization in July 2025 for its tobacco and menthol-flavored products, meaning the company has a proven track record of navigating the PMTA process. A Cool Mint application would not be JUUL's first rodeo. It would be an extension of an existing relationship with a regulator that just demonstrated new flexibility.

This regulatory shift did not happen in a vacuum. Prediction markets noticed, and Cool Mint's odds moved in a way that demands explanation.

---

Cool Mint Just Jumped 21 Percentage Points in the JUUL Relaunch Market

Cool Mint's implied probability in the "What flavors will JUUL relaunch?" market surged from 9% to 30% over three days, a +21 percentage point repricing. From its period low of 7%, the swing reaches +23 percentage points. At 9%, the market was pricing Cool Mint as a near-impossibility, a relic of JUUL's pre-enforcement era with no realistic path back. At 30%, the market is saying there is a roughly one-in-three chance this flavor returns to shelves before December 31, 2026.

The timing of this move aligns broadly with increased attention to the FDA's evolving posture on flavored ENDS, though the exact 72-hour catalyst is difficult to pin with certainty. The Glas authorization landed in early May, and additional regulatory actions, including the FDA's modified risk orders for Swedish Match's ZYN nicotine pouches in June 2026, have reinforced the narrative of a friendlier regulatory environment. Whether a single news item or the cumulative weight of multiple data points drove the repricing, the direction is unambiguous: traders are assigning materially higher odds to Cool Mint's return.

A 30% probability is not a prediction of success. It is an acknowledgment that the regulatory door, previously bolted shut, now appears ajar.

Prediction-market view

Live prices, venue by venue

Compare the latest YES price at each venue. Check market rules, liquidity, and fees before trading.

Mint

Consensus YES price across 1 venues

15%average

KalshiBest YES price16¢

Mango

Consensus YES price across 1 venues

6%average

KalshiBest YES price9¢

Cucumber

Consensus YES price across 1 venues

1%average

KalshiBest YES price9¢

Mint

Consensus YES price across 1 venues

52%average

PolymarketBest YES price98¢

---

Before the Ban, Cool Mint Was JUUL's Best-Selling Flavor, and That Commercial History Is Now Relevant Again

Cool Mint was not a niche product. It was JUUL's commercial engine. Before the company voluntarily pulled flavored pods from retail shelves in late 2019 under intense political and regulatory pressure, Cool Mint consistently ranked as JUUL's top-selling pod variant. The flavor bans that followed, targeting mango, fruit, creme, and cucumber alongside Cool Mint, stripped the company of its most popular SKUs while leaving only tobacco and menthol on the market.

JUUL's subsequent revenue decline tracked closely with that product lineup contraction. A relaunch strategy that includes only tobacco and menthol, both already authorized, recaptures a fraction of the brand's former addressable market. Adding Cool Mint back would restore the single highest-demand product in JUUL's historical portfolio.

This is why the Glas precedent matters more for Cool Mint than for hypothetical fruit or dessert flavors. Cool Mint occupies a flavor category (mint/menthol-adjacent) that the FDA has now shown willingness to authorize. The distance between "Classic Menthol" and "Cool Mint" is smaller than the distance between "Classic Menthol" and "Mango." JUUL's application for Cool Mint can point to the Glas decision and argue that the flavor profile falls within a zone the agency has already deemed acceptable, subject to adequate youth-access controls.

The commercial logic is clear. But does the regulatory logic actually hold? The FDA's new authorization is promising, yet the specific mechanics of what it means for JUUL's pending applications need scrutiny.

---

The Case Against Cool Mint: Why 30% Might Be Too High

The strongest counterargument is institutional, not scientific. JUUL is not Glas. JUUL spent years as the FDA's primary target in the youth vaping crisis, absorbing enforcement actions, congressional hearings, and a marketing denial order that the company had to fight in court. The political baggage JUUL carries is unique in the ENDS industry. Authorizing a Glas product that few teenagers have heard of is a different political act than authorizing Cool Mint from the brand synonymous with the teen vaping epidemic.

There is also a timing problem. Even if JUUL files a PMTA for Cool Mint tomorrow, FDA review cycles for major applications typically stretch months. The market resolves on December 31, 2026, giving the agency roughly four and a half months from today. The FDA authorized JUUL's tobacco and menthol products only after years of back-and-forth litigation and negotiation. A Cool Mint authorization within that window would require processing speed the agency has rarely demonstrated.

Additionally, the Glas authorization rested heavily on device-level age verification technology, including Bluetooth pairing and biometric checks. JUUL's existing hardware does not include comparable restrictions. The company would likely need to either develop new access-control technology or argue that alternative youth-mitigation measures are sufficient. That is a substantial application burden with a tight clock.

At 30%, the market is pricing in a real but minority probability. That number may be generous given the timeline constraints, or it may undercount the speed at which the current administration's pro-harm-reduction posture could accelerate review. The honest answer is that this is a close call, and the market reflects that ambiguity.

---

Resolution Timeline and What to Watch

This market resolves December 31, 2026. Between now and then, three signals will determine whether Cool Mint's 30% probability rises or falls. First, any public indication that JUUL has filed or intends to file a PMTA specifically for Cool Mint would be the single most bullish data point, converting speculation into confirmed corporate intent. Second, additional FDA authorizations of flavored ENDS products from other manufacturers would further erode the regulatory barrier. Third, any enforcement action or political backlash against the Glas authorization could reverse the precedent before JUUL can exploit it.

The broader regulatory environment under the current administration has tilted toward expanded market access for reduced-harm nicotine products. The FDA's press release on the Glas authorization explicitly cited President Trump's leadership in authorizing "less harmful alternatives for smokers." That political cover matters. It suggests the agency has top-level support for the direction it is moving.

Cool Mint's repricing from 7% to 30% is a rational response to a genuine shift in the regulatory environment. Whether the shift is large enough, and fast enough, to deliver a JUUL Cool Mint authorization by year-end remains the open question. At current odds, the market is saying: possible, not probable. Given the precedent, the commercial incentive, and the timeline, that pricing feels approximately right.